Madrigal pharmaceuticals reports first-quarter 2025 financial results and provides corporate updates

Conshohocken, pa., may 01, 2025 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq: mdgl), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (mash), today reports first-quarter 2025 financial results and provides corporate updates.
MDGL Ratings Summary
MDGL Quant Ranking